About Exscientia
Exscientia is a company based in Oxford (United Kingdom) founded in 2012 by Chris Gibson was acquired by Recursion in October 2024.. Exscientia has raised $428.63 million across 10 funding rounds from investors including Recursion Pharmaceuticals, Evotec and BlackRock. The company has 392 employees as of December 31, 2023. Exscientia has completed 1 acquisition, including Allcyte. Exscientia operates in a competitive market with competitors including Jazz Pharmaceuticals, C4 Therapeutics, Erasca, MiRagen and Mereo BioPharma, among others.
- Headquarter Oxford, United Kingdom
- Employees 392 as on 31 Dec, 2023
- Founders Chris Gibson
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Exscientia Plc
- Date of Incorporation 29 Jun, 2021
- Jurisdiction OXFORD, OXFORDSHIRE, UNITED KINGDOM
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$428.63 M (USD)
in 10 rounds
-
Latest Funding Round
$2.3 M (USD), Grant
Dec 05, 2023
-
Investors
Recursion Pharmaceuticals
& 16 more
-
Employee Count
392
as on Dec 31, 2023
- Investments & Acquisitions
-
Acquired by
Recursion
(Oct 10, 2024)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Unlock access to complete
Unlock access to complete
Leadership Team
32 people
Data Analysis and Operations Team
30 people
Software Development Team
21 people
Senior Team
12 people
Product Management Team
11 people
Board Team
8 people
Operations Team
7 people
Finance and Accounting
6 people
Unlock access to complete
Funding Insights of Exscientia
Exscientia has successfully raised a total of $428.63M across 10 strategic funding rounds. The most recent funding activity was a Grant round of $2.3 million completed in December 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 10
- Last Round Grant — $2.3M
-
First Round
First Round
(28 Sep 2017)
- Investors Count 16
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec, 2023 | Amount | Grant - Exscientia | Valuation |
investors |
|
| Oct, 2021 | Amount | Post-IPO - Exscientia | Valuation |
investors |
|
| Jul, 2021 | Amount | Grant - Exscientia | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Exscientia
Exscientia has secured backing from 17 investors, including institutional and venture fund investors. Prominent investors backing the company include Recursion Pharmaceuticals, Evotec and BlackRock. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital investments in technology and startups.
|
Founded Year | Domain | Location | |
|
Private equity and venture capital fund focused on the healthcare sector
|
Founded Year | Domain | Location | |
|
Multiple investment strategies are pursued by this hedge fund.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Exscientia
Exscientia has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Allcyte. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Developer of drugs for the treatment of cancer patients
|
2017 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Exscientia
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Exscientia Comparisons
Competitors of Exscientia
Exscientia operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, C4 Therapeutics, Erasca, MiRagen and Mereo BioPharma, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
|
| domain | founded_year | HQ Location |
Small molecule therapeutics for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
MicroRNA-based therapeutics are developed for treating multiple diseases.
|
|
| domain | founded_year | HQ Location |
Therapeutics for cancer and rare diseases are developed.
|
|
| domain | founded_year | HQ Location |
Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Exscientia
Frequently Asked Questions about Exscientia
When was Exscientia founded?
Exscientia was founded in 2012 and raised its 1st funding round 5 years after it was founded.
Where is Exscientia located?
Exscientia is headquartered in Oxford, United Kingdom. It is registered at Oxford, Oxfordshire, United Kingdom.
Who is the current CEO of Exscientia?
Chris Gibson is the current CEO of Exscientia. They have also founded this company.
Is Exscientia a funded company?
Exscientia is a funded company, having raised a total of $428.63M across 10 funding rounds to date. The company's 1st funding round was a Grant of $1.5M, raised on Sep 28, 2017.
How many employees does Exscientia have?
As of Dec 31, 2023, the latest employee count at Exscientia is 392.
What does Exscientia do?
Exscientia was founded in 2012 in Oxford, United Kingdom, and operates in the biotechnology sector. AI technologies are integrated to develop therapeutics, including the identification of drug candidates, molecule design, and preclinical experiments. Targeted therapies and personalized treatment strategies are emphasized. Research findings are published, and presentations are made in the field of precision medicine.
Who are the top competitors of Exscientia?
Exscientia's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Erasca.
How many acquisitions has Exscientia made?
Exscientia has made 1 acquisition, including Allcyte.
Who are Exscientia's investors?
Exscientia has 17 investors. Key investors include Recursion Pharmaceuticals, Evotec, BlackRock, Marshall Wace, and Gates Foundation.